Drug management for hypertension in type 2 diabetes in family practice

Canadian Family Physician

Volumn 55, Issue 7, 2009, Pages 728-734

  Putnam, Wayne ^a   Buhariwalla, Farokh ^b   Lacey, Kendrick ^c   Goodfellow, Mary ^b   Goodine, Rose Anne ^b   Hall, Jennifer ^c   MacDonald, Ian ^b   Murray, Michael ^b   Smith, Preston ^a   Burge, Fred ^a   Natarajan, Nandini ^a   Lawson, Beverley ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Community Health Centre ^*

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; RAMIPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CANADA; FEMALE; GENERAL PRACTICE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUTRON RADIATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RURAL AREA; SEX DIFFERENCE; URBAN AREA;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CANADA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FAMILY PRACTICE; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS;

EID: 67651172916     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. National Diabetes Surveillance System. Responding to the challenges of diabetes in Canada. Ottawa, ON: Health Canada; 2003. Available from: www.phac-aspc.gc.ca/ccdpc-cpcmc/ndss-snsd/english/pubs-reports/pdf/ WEB-NDSS-English-Report-nocover.pdf. Accessed 2009 May 11.
2. Harris SB, Ekoé JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70(1):90-97 (Pubitemid 41207652)
3. Supina AL, Guirguis LM, Majumdar SR, Lewanczuk RZ, Lee TK, Toth EL, et al. Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitus. Clin Ther 2004;26(4):598-606. (Pubitemid 38586461)
4. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002;25(1):199-201.
5. Hänninen JA, Takala JK, Keinänen-Kiukaanniemi SM. Blood pressure control in subjects with type 2 diabetes. J Hum Hypertens 2000;14(2):111-115
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160):703-13. Erratum in: BMJ 1999;318(7175):29.
7. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-64. (Pubitemid 30185779)
8. McLean DL, Simpson SH, McAlister FA, Tsuyuki RT. Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies. Can J Cardiol 2006;22(10):855-860
9. Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003;26(2):355-359 (Pubitemid 36929055)
10. Hicks LS, Fairchild DG, Horng MS, Orav EJ, Bates DW, Ayanian JZ. Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension 2004;44(4):429-434 Epub 2004 Aug 23.
11. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339(27):1957-1963 (Pubitemid 29024127)
12. Ménard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. CMAJ 2005;173(12):1457-1466 Epub 2005 Nov 17. (Pubitemid 41774943)
13. Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol 2006;22(7):583-593
14. WHO Collaborating Centre for Drug Statistics Methodology. Complete ATC index 2006. Oslo, NO: Norwegian Institute of Public Health; 2006. Available from: www.whocc.no/atcddd. Accessed 2006 Feb 13.
15. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. 41st ed. Ottawa, ON: Canadian Pharmacists Association; 2006.
16. Basile JN, Lackland DT, Basile JM, Riehle JE, Egan BM. A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich) 2004;6(1):18-25.
17. Jackson GL, Edelman D, Weinberger M. Simultaneous control of intermediate diabetes outcomes among Veterans Affairs primary care patients. J Gen Intern Med 2006;21(10):1050-1056 (Pubitemid 44337734)
18. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906. (Pubitemid 41265663)
19. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755- 1762 (Pubitemid 28269185)
20. Khan NA, Hemmelgarn B, Padwal R, Larochelle P, Mahon JL, Lewanczuk RZ, et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2007;23(7):539-550
21. Campbell NR, Tu K, Brant R, Duong-Hua M, McAlister FA; Canadian Hypertension Education Program Outcomes Research Task Force. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension 2006;47(1):22-28 Epub 2005 Dec 12. (Pubitemid 43177810)
22. Pellegrini F, Belfiglio M, De Berardis G, Franciosi M, Di Nardo B, Greenfield S, et al. Role of organizational factors in poor blood pressure control in patients with type 2 diabetes: the QuED Study Group - quality of care and outcomes in type 2 diabetes. Arch Intern Med 2003;163(4):473-480 (Pubitemid 36241026)
23. Schaars CF, Denig P, Kasje WN, Stewart RE, Wolffenbuttel BH, Haaijer-Ruskamp FM. Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Diabetes Care 2004;27(1):123-128 (Pubitemid 38196720)
24. Sequeira RP, Al Khaja KA, Damanhori AH. Evaluating the treatment of hypertension in diabetes mellitus: a need for better control? J Eval Clin Pract 2004;10(1):107-116 (Pubitemid 38233124)
25. McFarlane SI, Castro J, Kaur J, Shin JJ, Kelling D Jr, Farag A, et al. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) 2005;7(2):73-80.
26. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427.
27. 2001 Census. Visible minority population, by province and territory (Newfoundland and Labrador, Prince Edward Island, Nova Scotia, New Brunswick). Ottawa, ON: Statistics Canada; 2005. Available from: www40.statcan.ca/l01/cst01/ demo52c.htm. Accessed 2009 May 11.
28. Myers MG. Automated blood pressure measurement in routine clinical practice. Blood Press Monit 2006;11(2):59-62. (Pubitemid 44090017)